Updated 2026*
The rise of GLP-1 medications, first used to treat type 2 diabetes and later approved in some forms for chronic weight management, has sparked a debate over where medical need ends and cosmetic use begins. In the U.S., Ozempic (semaglutide) and Victoza (liraglutide) are approved to help manage type 2 diabetes. Wegovy and Saxenda contain the same active ingredients, respectively, and are approved for long-term weight management in eligible patients.
As more people turn to prescription weight-loss drugs to lose a few pounds, experts disagree over whether healthy adults should be able to use them for cosmetic reasons. Some worry about side effects and whether wider use could make it harder for patients who rely on these drugs to get them. Others argue that adults should be free to make that choice with their doctor.
Weight-Loss Drugs for All Who Want It!
Potential Benefits for Well-Being
Weight stigma and poor body image can hurt confidence and self-esteem in ways a BMI score can’t capture. In consumer surveys, roughly 35% to 44% of GLP-1 users reported improvements in body image or self-confidence. People said they felt more comfortable posing for photos, wearing fitted clothes, or going out with friends. For people caught in cycles of dieting or frequent food cravings, appetite-suppressing medication may give them some mental breathing room. Spending less time thinking about food, counting calories, or worrying about what to eat can free up attention for other parts of daily life. How patients feel in their own bodies deserves a place in the prescribing decision, even if it’s only for cosmetic reasons.
The Cosmetic Surgery Parallel
Adults can choose invasive cosmetic procedures such as liposuction or breast augmentation after discussing the risks with a doctor. Why shouldn’t the same principle apply to prescription weight-loss drugs? Adults who understand the potential benefits, side effects, and alternatives should have a say in the decision, while doctors decide whether prescribing is medically appropriate. The American Board of Cosmetic Surgery describes medication-assisted weight loss as an option in cosmetic care, and a review examines the role of GLP-1 drugs in plastic surgery. If doctors can consider a patient’s appearance goals when deciding whether to operate, they should be able to consider those same goals when deciding whether to prescribe a weight-loss drug.
Harm Reduction and Safety
When a prescription is out of reach, people who still want weight-loss drugs may go to online sellers that don’t require one. In a small study published in JAMA Network Open, all three semaglutide samples researchers received from illegal online sellers contained 29% to 39% more of the drug than their labels stated. The FDA has also received reports of dosing errors involving compounded semaglutide, some even requiring hospitalization for users. Allowing regulated access for cosmetic use could give adults a safer route to obtain a verified product from a licensed pharmacy, with clear dosing instructions and follow-up care.
The Fat Risks of Weight-Loss Drugs for Cosmetic Purposes
A Few Pounds, Real Health Risks
When it comes to health vs. appearance, the potential risks for a healthy individual may outweigh the main pro: an “ideal” appearance. The potential side effects of GLP-1 medications for a non-diabetic or overweight individual have the power to interrupt elements of daily life. In clinical trials involving adults who qualified for weight-loss treatment, 44% of those receiving Wegovy injections reported nausea and 24% reported vomiting. Among those receiving a placebo, 16% reported nausea and 6% reported vomiting. Using GLP-1 drugs when a person is already at a healthy or low body weight can trigger adverse physiological effects, including muscle wasting, severe gastrointestinal distress, acute pancreatitis, and gallbladder disease. For a healthy adult, those side effects are a steep price to pay for losing a few pounds for appearance alone.
Supply Shortages For Those in Need
GLP-1 drugs have surged in popularity as a quick way to lose weight, including for people looking to shed a few pounds for cosmetic reasons. That growing market has added pressure to an already strained supply chain. By 2026, roughly 11% of U.S. adults reported using GLP-1 medications specifically for weight loss. When orders pile up faster than biomanufacturers can produce the drugs, supply shortages quickly follow. If primary GLP-1 medications aren’t accessible, doctors may have to reduce doses, pause treatment, or switch patients with type 2 diabetes to older medications that can be harder to tolerate. In one study, 23.6% of patients affected by GLP-1 shortages saw their HbA1c, a measure of average blood sugar, rise by more than one percentage point. The FDA declared the nationwide shortages of injectable Tirzepatide and Semaglutide resolved in December 2024 and February 2025. However, some liraglutide doses remained on back order in 2026, and dulaglutide was still hard to find at some pharmacies.
Increase in Counterfeits
Weight-loss drugs have taken over social media, with celebrities and influencers showing off the drugs’ effectiveness. In the UK alone, a study found that an estimated 1.6 million people reported using weight loss medication. Without insurance or discounts, GLP-1 drugs can cost over $1,000 a month in the U.S. The competitive demand and high costs have created an opportunity for counterfeit sellers to tap into a massive market. In October 2025, UK authorities reported a record seizure of £250,000 worth of trafficked weight-loss drugs, including thousands of retatrutide pens. Purchasing counterfeit versions from unregulated sellers can result in major health risks and even death. As more consumers buy these products online, the FDA has warned buyers about the risks and sent warning letters to companies marketing them.
The Bottom Line: The debate over cosmetic use of GLP-1 drugs weighs an adult’s freedom to make an informed choice with their doctor against the health risks and the need to protect access for patients who rely on them. Wider prescribing could give some people a safer alternative to unregulated sellers, but it would also only add to the competitive demand.
